The present study tested the hypothesis that ERK activation is an essential step in the onset of labor in a rat model of preterm labor. The administration of RU486, an antiprogesterone agent, to rats induced preterm delivery 22.2±0.24 hrs after treatment.
INTRODUCTION
In the U.S., approximately 10% of all births are premature. Premature birth accounts for approximately 75% of all neonatal mortality and morbidity including longterm disabilities (1, 29). However, at present, there is no truly safe and effective agent approved in the U.S. for the selective suppression of preterm uterine contractions (40) . A greater understanding of the mechanisms of uterine contraction during preterm labor and term labor is sorely needed for more effective and specific therapeutics to be developed.
Caldesmon (CaD) is an actin-binding protein that inhibits actin activated ATPase activity in vitro and has been proposed to be a major regulator of smooth muscle actinmyosin interactions (30). In vitro, either the binding of calmodulin or phosphorylation of
CaD can reverse the inhibition (reviewed in (30)). It is clear that ERK can phosphorylate
CaD in vitro and in vivo (2, 3, 4, 12) , however, whether ERK regulates the inhibitory action of CaD and muscle contractility in vivo remains a controversial area (13, 17, 35) .
It has been difficult to determine a clear-cut, cause and effect relationship between ERK activity and regulation of contractility in a physiological setting.
The ERK pathway is known to be activated during oxytocin-induced contraction (36) and during prostaglandin F2alpha-induced contraction of pregnant rat myometrium (37) . Furthermore, we have previously published that spontaneous term labor in the rat is associated with a basal activation of ERK2 and subsequent phosphorylation of CaD that persists in vitro (28). Thus it is hypothesized that the change in ERK/CaD signaling may contribute to the change in uterine contractility during the initiation of parturition. The currently available ERK inhibitors are only effective when used as pretreatment to prevent the initial activation of ERK. Thus, it has not been possible by simple in vitro R-00042-2004R3 4 experiments to determine whether there is a cause and effect relationship between gestation-dependent activation of the ERK/CaD pathway and regulation of uterine contractility. To the best of our knowledge, the in vivo effect of ERK inhibition on modulating smooth muscle contractility has not been previously explored.
In the present study, we found 1) that RU486-induced preterm labor displays a similar in vitro biochemical profile in uterine muscle tissue as that caused by spontaneous labor and; 2) that ERK inhibition by U0126 delays RU486 induced preterm labor in a statistically significant manner.
MATERIALS AND METHODS
Animals and treatment groups. All procedures were approved by our institutional animal care and use committee (IACUC). Sprague-Dawley primigravid pregnant rats (day 1 = sperm positive, Taconic, Germantown, NY; time 0 was arbitrarily taken as midnight) were used for the experiments. The female rats were mated overnight and the vaginal plugs were checked on the following morning between 7am and 10am, including the mornings on the weekends. The rats were housed in a constant-temperature room with a 12-hr light and 12-hr dark cycle. Food and water were available ad libitum. The rats were divided into five groups: sham, RU486 treated (RU), labor matched U0126+RU486 treated (U0+RU), time-matched UO+RU and spontaneous labor (SL).
The dosage schedule versus gestational stage is illustrated in Fig. 1 .
Induction of preterm labor:
In the RU group (Fig.1A) , rats (n=6) were treated with RU486 subcutaneously (SC) at dose of 2mg/kg (concentration of 3mg/ml in sunflower seed oil) at 10am on day 19 of pregnancy. Then the rats were closely observed for signs of labor on day 20 of pregnancy.
U0126 treatment:
In the labor matched U0+RU group (Fig.1A) , 18-day pregnant rats (n=6) were treated with U0126 at dose of 100mg/kg, SC, q8h (7am, 3pm and 11pm) (maximal safe dose in rats, personal communication, James Trzaskos, Bristol Myers Squibb). U0126 was dissolved at a concentration of 200mg/ml in DMSO. On day 19 of pregnancy, the rats were administrated RU486 at 10am for preterm labor induction. The U0126 treatment continued till the delivery of the first pup.
In the time-matched U0 +RU group (Fig.1A) : 18-day pregnant rats (n=6) were injected with U0126 and RU486 following the dose schedule for the labor matched U0+RU group, but the rats were euthanized exactly at the average time at which the group receiving only RU486 (RU group) delivered the first pup, i.e. 22.2 hrs after RU486 administration.
Sham control (Fig.1B) : 18-day pregnant rats (n=6) were injected subcutaneously with same amount of DMSO or sunflower seed oil in the regime described for the U0+RU groups. The rats were euthanized via CO 2 inhalation at 11am of day 20 pregnancy for sample collection to compare a nonlaboring state at a similar average stage of gestation as that where the labor matched U0+RU treated rats and the RU treated rats delivered.
Tissue preparation and force recording. For the collection of in-labor uterine smooth muscle samples, rats were closely observed at 15-30 minute intervals. The delivery of the first pup was defined as an index of labor. Rats were euthanized by carbon dioxide inhalation followed by cervical dislocation. The pups were euthanized by CO 2 and also all products of conception were removed from the uterine wall and placed on ice. The blotted weight of the pups was recorded. Excised uteri were immersed immediately into oxygenated Krebs solution at room temperature. The composition of Krebs solution was (mM): 120 NaCl, 5.9 KCl, 11.5 Dextrose, 25 NaHCO 3 , 1.2 NaH 2 PO 4 .H 2 O, 1.2 MgCl 2 .6H 2 O, and 2.5 CaCl 2. Approximate 8x2 mm (LxW) whole thickness uterine strips oriented parallel to the long axis of the longitudinal muscle bundles were dissected under a dissection microscope (Olympus VM, Japan).
Isometric force was recorded at 37°C as previously described (28, 42). All myometrial strips were 8mm long at slack length and were gradually stretched to the optimal length (Lo) with respect to spontaneous contractions (21 The antiprogesterone RU486 has been used to induce a reliable model for preterm labor/birth in pregnant rats (6, 16, 43) . In the present study, pregnant rats were injected subcutaneously with RU486 at 10am of the nineteenth day of gestation ( 
RESULTS

RU486 induces narrowly timed preterm labor in
Strips from RU486 treated animals display increased myometrial contractility in
vitro. The fact that RU486 can induce preterm labor implies an effect on myometrial contractility; however, whether this increased contractility is associated with chronic changes in basal contractility that persist in vitro in the absence of the hormonal milieu of the intact rats has not been previously shown. Thus, we compared the in vitro area under force curves (AUC) in the sham group, RU group and spontaneous labor (SL) group. As described previously (28), the in vitro myometrial strips were relatively quiescent on day 20 of pregnancy ( Fig.3A , sham group) displaying a lower AUC after normalization to tissue dry weight (1532±152 mN⋅s /mg) compared to myometrial strips from rats in spontaneous labor (Fig.3A , SL group). In vitro uterine contractility increased dramatically after in vivo RU486 treatment (Fig. 3A , RU group, AUC 3815±449 mN⋅s /mg), comparable to that during spontaneous labor (AUC 4201±924 mN⋅s /mg, p=0.69).
ERK2 is activated during RU486-induced preterm labor. We have previously reported that spontaneous labor is associated with phosphorylation, and, hence, activation of ERK2 and subsequent phosphorylation of CaD and that theses changes persist in vitro (28). The question arises as to whether RU486-induced preterm labor causes the same changes in basal ERK2 and CaD phosphorylation as occurs in spontaneous labor.
Muscles were quick-frozen in vitro after a force recording experiment as described in
Methods. ERK2 protein levels did not change in any group (Fig.3D) ; however, ERK2
phosphorylation levels normalized to ERK2 protein levels significantly increased during RU486-induced labor (Fig. 3B , RU group) to a level comparable to that seen in spontaneous labor (Fig 3B, SL group) .
We have previously reported that ERK1 protein levels and phospho-ERK1 levels in protein-matched samples are not detectably changed throughout pregnancy into spontaneous labor (28). Similarly, in the current study, there was no detectable change in ERK1 protein levels between sham, SL, and RU groups (Fig 3D) . Phospho-ERK1 levels, normalized to ERK-1 protein levels, also did not change detectably during RU486-induced preterm labor (Fig 3C) . 
3E, SL group).
Basal 20-kDa myosin light chain phosphorylation (LC20-P) levels increased
during RU486-induced preterm labor. Smooth muscle contraction can be regulated both by pathways that terminate on the thin filament and those that terminate on the thick filament (23). In our experience, it is not possible to measure consistent levels of LC20-P in quick-frozen rat myometrial muscles because the exposure to cold buffers triggers a contraction response, presumably due to Ca released from intracellular stores (5, 32) . For this reason, we have permeabilized the muscles with alpha-toxin and clamped Ca at resting levels (pCa7). This approach also gives a measure of the Ca sensitivity of LC20-P since the measurements are made at a constant intracellular [Ca 2+ ]. We have previously reported that a small, but significant, increase in basal 20 kDa myosin light chain phosphorylation. Thus, the question arises as to whether a similar biochemical profile is seen in vitro for LC20-P in strips from RU486-treated animals. LC20-P levels were significantly increased from 0.12±0.017mole phosphate/mole LC20 (in sham group) to 0.17±0.014 in myometrium during RU486-induced preterm labor (Table 1. ). An LC20-P level of 0.40±0.033mole phosphate/mole LC20 in 51mM KCl stimulated (for 4min) myometrial strips was used as a positive control. In general, an increase in basal LC20
phosphorylation would tend to increase contractility during labor. Treatment with U0126 delayed the onset of parturition in a statistically significant manner to an average of 25.2±0.64 hrs after RU486 administration (Fig. 4, p<0 .01 compared to animals treated with RU alone). As is seen in Fig. 4 , there is no overlap of the labor onset times between the RU group and the U0+RU group.
The MEK inhibitor U0126 delays
Interestingly, despite the fact that U0126 delayed RU486-induced preterm labor, once labor commenced (albeit at a later point in time), the myometrial AUC for the labor matched U0+RU group (3466±624 mN⋅s /mg) was not significantly different from that for the laboring animals treated with RU486 alone (3815±449 mN⋅s /mg) or those in spontaneous labor (4201±924 mN⋅s /mg). Similarly p-ERK/ERK ratios and the pCaD/CaD ratios in the labor-matched U0+RU group (10.7 ±1.6 and 22.6±2.9 respectively) were indistinguishable from those parameters in laboring animals treated with RU486 alone (11.1±1.3 and 24.6±3.8 respectively) or those in spontaneous labor (13.6±3.4 and 32.2±3.0 respectively). Thus, increased in vitro contractility, increased ERK activation and increased CaD phosphorylation appear to be diagnostic of labor no matter when occurs.
U0126 Inhibits the RU486-induced Increase in ERK Phosphorylation, CaD
Phosphorylation and in vitro Contractility in Time-matched Animals. As stated above, once the labor commenced, the in vitro contractilities, p-ERK, p-CaD and p-LC20 levels of labor-matched groups (SL, U0+RU and RU groups) were all significantly increased compared to the sham group. A key question is whether the MEK inhibitor actually prevented ERK activation. Thus, we also studied an additional control group of animals treated with U0126 and RU486 for which the animals were sacrificed at exactly the average time point after RU486 administration at which the animals receiving RU486 alone went into labor (see Materials and Methods). In these time-matched groups, there was indeed a significant effect of U0126 to inhibit the RU486-induced increase in in vitro contractility (Fig. 5A ), ERK2 phosphorylation (Fig. 5B) , and CaD phosphorylation (Fig.   5E ) during the time that labor was delayed. Neither ERK1 nor ERK2 protein levels ( Fig   5D) nor h-CaD protein levels (Fig. 5F ) nor ERK1 phosphorylation levels (Fig. 5C ) were significantly changed between these groups.
U0126 Does Not Prevent the RU486-induced Increase in the LC20
Phosphorylation Level. As is shown in Table 1 RU486 induced preterm labor is associated with a small, but significant increase in LC20-P level. Others have suggested that ERK may be able to regulate LC20 phosphorylation levels by using MLCK as a substrate (11, 25, 31, 34) . However, U0126 pretreatment did not prevent the RU486-induced increase in the LC20-P level. The LC20-P levels in the RU group are not statistically significantly different from those in the time-matched U0+RU group (Table   1) . These results are consistent with the idea that the main target of the ERK-mediated pathway in this system is CaD rather than MLCK. These results, in contrast, are not consistent with the idea, cited above, that ERK is regulating LC20 phosphorylation in this system.
Effect of U0126 on Fetal Weight. It is worth noting that even though ERKs are
present ubiquitously in most cells of the body; we observed no obvious signs of toxicity of U0126 to the mothers or pups in this rat model. There were no differences in daily weight gain or general behavior in pregnant rats between the U0+RU group and the RU group (data not shown). U0126 treatment did not affect fetal weight (Table 2. ). The duration of pregnancy and labor in the rat model is much shorter than that in the human (averaging 23 days versus 266 days, 12X longer in the human). Thus, a 3 hr delay in the rat model can be thought of as being roughly equivalent to at least 36 hrs in the human. Indeed, in the case of the oxytocin receptor antagonist cited above, this agent caused a prolongation of pregnancy of up to 7 days (40) . This degree of delay in delivery of a premature infant allows sufficient time to transfer the mother and fetus to the appropriate hospital and implement betamethasone treatment, which will induce maturation of the fetal lungs and significantly decrease the likelihood of respiratory distress syndrome (15) .
DISCUSSION
Thus, the MEK/ERK pathway may provide useful targets for the future development of therapeutic agents. However, even though we did not detect obvious toxicity of U0126 to the rats in this study, we also did not attempt to screen thoroughly for toxic effects and do not intend to imply that this particular MEK inhibitor could be directly used therapeutically. In the present study U0126-treated animals were monitored between day 18 and 20 of pregnancy; thus, most developmental changes in the fetus were nearing completion. Another study has demonstrated inhibitory effects of PD98059 and U0126 on the development of kidneys cultured in vitro from 15 day embryos (22) . In the present study we did not investigate whether such effects could be demonstrated in our animals, but this raises the possibility that additional effects of U0126 on other organs may exist.
Another finding of the present study is that RU486-induced labor in vivo is associated with a persistent increase in myometrial contractility in vitro, suggesting longterm changes. Although it is known that RU486 is a progesterone receptor antagonist, its subcellular mechanism of action on uterine contractility has not been known. The effect of RU486 is unlikely to be a direct action on contractile proteins since RU486 is a progesterone nuclear receptor antagonist (19) . In contrast to contraction, RU486 actually relaxed KCL-induced contraction of rat nonpregnant uterine smooth muscle in vitro (38) .
In the present study, the in vitro persistent increase in contractility caused by in vivo administration of RU486 could be either due to a consequence of progesterone-related signal transduction or an indirect consequence resulting from labor commencing. We have shown that the subcellular mechanisms of RU486 on uterine contractility include, but may not be limited to, activation of the ERK/CaD signaling pathway and increased basal LC20 phosphorylation. The upstream signaling events causing these changes remain to be determined, but it is of considerable interest that tissues taken from rats undergoing spontaneous labor and RU486-induced preterm labor display identical 
